Skip to Content

News Releases

News Releases

Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity
June 22, 2020
Additionally, Sutro's partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration's pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1 SOUTH SAN FRANCISCO, Calif.
Sutro Biopharma Announces Proposed Public Offering
May 11, 2020
SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF ® , to create a broad variety of
Sutro Biopharma Appoints James Panek to Board of Directors
January 8, 2020
SOUTH SAN FRANCISCO, Calif. , Jan. 8, 2020 /PRNewswire/ --  Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics,